CPP-109 vigabatrin + Matching Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Methamphetamine Dependence
Conditions
Methamphetamine Dependence
Trial Timeline
Jul 1, 2008 → Nov 1, 2009
NCT ID
NCT00730522About CPP-109 vigabatrin + Matching Placebo
CPP-109 vigabatrin + Matching Placebo is a phase 2 stage product being developed by Catalyst Pharmaceuticals for Methamphetamine Dependence. The current trial status is terminated. This product is registered under clinical trial identifier NCT00730522. Target conditions include Methamphetamine Dependence.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00730522 | Phase 2 | Terminated |
Competing Products
6 competing products in Methamphetamine Dependence
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| A single oral 5 mg of duterium labeled methamphetamine | Pacific Biosciences | Approved | 77 |
| Dextroamphetamine + Placebo | Pacific Biosciences | Phase 2 | 44 |
| modafinil | Pacific Biosciences | Phase 2 | 44 |
| Naltrexone | Pacific Biosciences | Phase 2 | 44 |
| Modafinil | Pacific Biosciences | Phase 2 | 44 |
| Ibudilast 20mg + Ibudilast 50mg + Placebo oral tablet | MediciNova | Phase 1 | 25 |